We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Isotretinoin REMS Proving Effective, Drugmaker Complaints Muted
Drugmakers have cited the risk evaluation and mitigation strategy (REMS) for acne drug isotretinoin as one of the FDA’s more burdensome REMS, but industry officials and experts are now applauding the program, with some calling it a perfect pilot candidate for standardization.